For the millions of adults navigating the dangerous intersection of chronic kidney disease and cardiovascular dysfunction, treatment options that address both simultaneously — without trading one harm for another — remain elusive. A new narrative review synthesizes the mechanistic rationale and large-scale clinical evidence for finerenone, a non-steroidal mineralocorticoid receptor (MR) antagonist, suggesting it may represent a meaningful step forward in managing this intertwined pathophysiology.
The review centers on the role of MR overactivation as a driver of cardiorenal injury independent of blood pressure — a distinction with real therapeutic significance. Finerenone's pharmacological profile diverges from older steroidal MR antagonists (spironolactone, eplerenone) through greater receptor selectivity, more balanced distribution across cardiac and renal tissues, and differential cofactor recruitment that amplifies anti-inflammatory and antifibrotic signaling. The FIDELIO-DKD and FIGARO-DKD trials — enrolling tens of thousands of patients with type 2 diabetes and chronic kidney disease — demonstrated statistically significant reductions in both kidney disease progression and major cardiovascular events. The pooled FIDELITY analysis reinforced these findings across a broader patient spectrum, while the more recent FINEARTS-HF trial extended cardiorenal protection to heart failure with preserved or mildly reduced ejection fraction, irrespective of diabetes status. Hyperkalemia, the historically limiting adverse effect of this drug class, remained infrequent under structured electrolyte monitoring.
This review arrives at a moment when the cardiorenal axis is receiving sustained scientific attention alongside GLP-1 receptor agonists and SGLT2 inhibitors. Finerenone's mechanism is complementary rather than redundant — targeting fibrosis and neurohormonal inflammation rather than glycemic or hemodynamic pathways — which raises genuine questions about combination therapy synergies. As a narrative review, however, this work synthesizes rather than generates evidence, and selection bias in source literature is an inherent constraint. The signals on retinal and hepatic outcomes remain preliminary. Still, the consolidation of mechanism, trial data, and emerging indications in a single analytical framework makes this a useful reference point for clinicians and researchers tracking the evolving pharmacology of cardiorenal protection.